CANCER RESEARCH INSTITUTE

Fast Facts

Key Achievements:

- $225 million invested in cancer immunology
- More than 3,100 scientists funded around the world
- Validated the theory that the immune system naturally sees, attacks, and eliminates cancer, and that this natural cancer-fighting power can be enhanced through immunotherapy
- Fundamental aspects of cancer immunity identified and characterized, which now are being exploited to save lives of cancer patients
- Through its vital support for and leadership in cancer immunology for 60 years, CRI has made these and other treatments possible:
  - Provenge™ - prostate cancer vaccine
  - Yervoy™ - melanoma antibody
  - BCG – bladder cancer treatment
  - Blockbuster antibody treatments Herceptin (breast cancer) and Rituxan (lymphoma)

CRI: Revolutionizing Cancer Treatment

The Cancer Research Institute (CRI) pioneered and leads global efforts to transform cancer patient care and save more lives through discovery and development of treatments that unleash the cancer-fighting powers of the immune system.

Founded in 1953, CRI has established and fostered a global community of scientists focused on discovering how to harness the immune system to fight cancer. Today, CRI drives international collaborative research initiatives that bring new, immune-based treatments to patients faster.

CRI scientists are turning knowledge about the immune system into powerful, smarter cancer vaccines, medicines, and other therapies. This new way to treat cancer—immunotherapy—is saving and extending the lives of cancer patients, giving them safer, more effective options and new hope.

CRI has invested more than $225 million in research conducted by more than 3,100 scientists and clinicians worldwide, hosts seminal international conferences and workshops devoted to furthering progress in the field, and honors leading scientific figures for their important contributions to cancer patient health. CRI grantees have gone on to win the Nobel Prize, head major cancer centers, and make discoveries leading to new treatment breakthroughs that are saving lives.

The Promise and Power of Cancer Immunotherapy

Our immune systems are capable of killing cancer, wherever it is in the body. In many healthy adults, the immune system does this naturally. Immunotherapies help restore immune protection in patients whose immune systems can no longer keep cancer at bay without help.

Cancer vaccines coach the immune system to find and attack cancer only (leaving healthy cells unharmed), and proteins called antibodies sustain that targeted attack long enough to destroy tumors.

Immunotherapy offers patients much-needed treatments that are safe and more likely than conventional treatments to keep cancer from coming back. It is also fundamentally changing how oncologists approach cancer treatment. Immunotherapy also can be used in combination with chemotherapy or radiation, resulting in fewer bad side effects and greater chance of patient survival.

2012 Expenses



Overhead expenses

15%

Cancer Research Institute Programs

CRI's programs span from laboratory research to clinical discovery and immunotherapy development. These complementary efforts allow CRI to achieve its goal to save the lives of more—and eventually all—cancer patients. Our programs:

Support in-depth laboratory research to understand the mechanisms of the immune system and how it responds to cancer

Deliver promising new treatments to patients in clinical trials

Bridge the lab and the clinic to optimize current treatment approaches

Forge collaborations between academics, industry, government, nonprofits, and patients

Disseminate knowledge through annual scientific meetings & the open access journal *Cancer Immunity*

Raise awareness about the power of immunotherapy to transform the treatment of all cancers

CRI's programs include:

- **Education and Early Career Training**
  - **CRI Irvington Postdoctoral Fellowship Program**
    Outcomes: 1,227 fellows supported since 1971; they are responsible for many key contributions to cancer immunology. Most fellows continue to work in the field in positions of leadership at the world's top academic institutions, such as Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, GlaxoSmithKline, Bristol-Myers Squibb, and many others.
  - **Student Training and Research in Tumor Immunology (STaRT) program**
    Outcomes: Since 2001, tumor immunology training programs established at 9 major universities; of 140 postgraduate students trained, 84% continue to advance in careers in scientific & medical research
- **Cancer Treatment Research & Development**
  - **Cancer Vaccine Collaborative**
    The centerpiece of our clinical research and development initiatives, the Cancer Vaccine Collaborative (CVC) is a global network of scientists at 21 clinical trial sites in the U.S., Europe, Japan, and Australia, who work together on coordinated, centralized studies of cancer vaccines.
    Outcomes: 1,050 patients treated since 2001; 50 early-phase cancer vaccine clinical trials launched or completed; 76 vaccine variables tested and systematically evaluated; accelerated improvement in vaccine design based on iterative, parallel trials, resulting in stronger anti-cancer immune responses.
  - **Cancer Vaccine Acceleration Fund**
    Innovative venture philanthropy fund that partners with biotechnology and pharmaceutical companies to bring highly promising immunotherapies into clinical trials faster
    Outcomes: 2 drugs sourced for CVC clinical trials (anti-GITR, poly-ICLC) and supplied to scientists outside of the CVC network (poly-ICLC only); the first, anti-GITR, would potentially never have been tested in cancer patients had CRI not intervened. 3 additional antibodies sourced through deal with MedImmune (anti-CTLA-4 (Tremelimumab), anti-OX-40, and anti-B7-H1 (or anti-PD-L1) for CVC clinical trials.
  - **Cancer Immunotherapy Consortium**
    An association of 120 biotech & pharmaceutical companies and academic institutions focused on late-stage drug development, government regulatory issues, and cancer patient care
    Outcomes: Established new criteria for evaluating cancer immunotherapy effectiveness; determined minimal standards for data sharing of immunological monitoring assays; identified best practices in immunological monitoring.
  - **Clinic and Laboratory Integration Program (CLIP)**
    Catalytic support for translational laboratory studies designed to answer new scientific questions that arise in the clinic, with special focus on improving immunotherapy for cancer patients
    Outcomes: This program, launched in late 2011, is providing critical catalytic support to 4 investigators.